Serum KL-6 level and DTPA clearance in systemic sclerosis patients
H. Sato, N. Goh, R. Janssen, J. C. Grutters, S. Veeraraghavan, P. Pantelidis, A. U. Wells, K. I. Welsh, N. Kohno, R. M. du Bois (London, United Kingdom; Nieuwegein, The Netherlands; Hiroshima, Japan)
Source: Annual Congress 2002 - Interstitial lung disease
Session: Interstitial lung disease
Session type: Oral Presentation
Number: 3677
Disease area: Interstitial lung diseases
Abstract KL-6 is a mucin-like glycoprotein expressed on type II pneumocytes in the lung. Serum KL-6 level has been suggested as a marker for fibrosis in interstitial lung disease. Clearance of diethylenetriamine penta-acetate (DTPA) from the lungs is useful in distinguishing fibrosing alveolitis from vascular disease in systemic sclerosis (SSc). For this study, we defined clinical fibrosis on the basis of HRCT scanning on 58 patients with SSc (lSSc; n = 29, dSSc; n = 29). Serum level of KL-6 measured by ELISA and DTPA clearance were co-compared and independently compared with HRCT defined fibrosis. In 53 patients, synchronous data on DTPA scanning were available. Serum KL-6 levels in lSSc were higher than in dSSc (1704U/mL vs 1414U/mL), but there was not a significant difference between them (p = 0.55). KL-6 levels in SSc patients with clinical lung fibrosis were significantly elevated compared to SSc patients without lung fibrosis (1959 +/- 1483U/mL vs. 412 +/- 71U/mL, resp.; χ 2 = 48.0, p < 0.0001). There was a strong correlation between impaired DTPA clearnace and presence of lung fibrosis (χ 2 = 30.9, p < 0.0001), and KL-6 levels significantly correlated with DTPA clearance (r = -0.74, χ 2 = 23.7, p < 0.0001). In conclusion, KL-6 levels and DTPA clearance are clearly associated with lung fibrosis in SSc patients, however in this group of patients, KL-6 proved the more significant marker for lung fibrosis.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Sato, N. Goh, R. Janssen, J. C. Grutters, S. Veeraraghavan, P. Pantelidis, A. U. Wells, K. I. Welsh, N. Kohno, R. M. du Bois (London, United Kingdom; Nieuwegein, The Netherlands; Hiroshima, Japan). Serum KL-6 level and DTPA clearance in systemic sclerosis patients. Eur Respir J 2002; 20: Suppl. 38, 3677
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Serum levels of chitotriosidase in pulmunary sarcoidosis Source: Annual Congress 2008 - COPD and other environment-related lung diseases Year: 2008
Serum KL-6 identifies ILD patients with a progressive fibrosing phenotype Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020
Serum lipid levels in patients with bronchiectasis Source: Annual Congress 2008 - Aetiology of respiratory infections: mycobacteria and fungi Year: 2008
Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis Source: Eur Respir J 2014; 43: 1530-1532 Year: 2014
Serum KL-6 as a marker of disease progression in SSc-ILD Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018
Serum concentrations of KL-6 in patients with IPF and lung cancer and serial measurements of KL-6 in IPF patients treated with antifibrotic therapy Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021
KL-6 serum levels in adult cystic fibrosis patients Source: Annual Congress 2011 - Cystic fibrosis: clinical and laboratory studies Year: 2011
Serum uric acid levels among COPD patients Source: Eur Respir J 2003; 22: Suppl. 45, 435s Year: 2003
Serum neopterin and IL-6 as biomarkers in patients with COPD. Source: International Congress 2017 – Novel molecular and genetic targets in COPD Year: 2017
Correlation of HRCT proven inflammatory changes with serum levels of ACE, sIL-2r and calciuria in pulmonary sarcoidosis Source: Eur Respir J 2003; 22: Suppl. 45, 226s Year: 2003
Serum KL-6 and SP-D as useful clinical indicators of interstitial changes and pulmonary functional abnormality in patients with Sjogren's syndrome Source: Eur Respir J 2001; 18: Suppl. 33, 367s Year: 2001
Usefulness of serum procalcitonin in lung cancer patients with elevated serum C-reactive protein level Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011
Serum uric acid levels among patients with COPD exacerbations Source: Eur Respir J 2006; 28: Suppl. 50, 33s Year: 2006
Prognostic role of CCL18 serum concentrations in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 574s Year: 2007
Increased CCL18 serum levels in patients with pulmonary fibrosis which reflect disease severity Source: Eur Respir J 2005; 26: Suppl. 49, 21s Year: 2005
YKL-40 and KL-6 in serum and sputum samples of patients diagnosed with hypersensitivity pneumonitis. Source: International Congress 2019 – Environment, work and respiratory health in occupational and environmental lung diseases Year: 2019
Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis Source: Eur Respir J 2011; 38: 1355-1360 Year: 2011
Serum C-reactive protein concentrations in patients with sarcoidosis: can be taken this simple test as an activation marker in sarcoidosis? Source: Eur Respir J 2004; 24: Suppl. 48, 712s Year: 2004
Elevated serum inflammatory markers in patients with stable COPD Source: Annual Congress 2009 - Respiratory mechanics, tissue and cell dysfunction in pulmonary disease Year: 2009
Serum YKL-40 modulation in severe asthma patients treated with Mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020